KPIs & Operating Metrics(New)
Breakdown Of AssetsDiaggregated Revenue AnnualDiaggregated Revenue Mix Annual %Disaggregated RevenueDisaggregated Revenue Mix %Employee StatisticsNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %Opex As A % Of RevenueOPEX BreakdownProperty And Equipment, NetRevenueRevenue AnnualRevenue From PayorsRevenue From Payors AnnualRevenue Mix From Payors %Revenue Mix From Payors Annual %Test Reports DeliveredTest Reports Delivered BreakdownTest Reports Delivered Total
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Castle Biosciences (CSTL) Revenue (2018 - 2025)

Historic Revenue for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to $83.0 million.

  • Castle Biosciences' Revenue fell 319.3% to $83.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $343.5 million, marking a year-over-year increase of 1014.88%. This contributed to the annual value of $332.1 million for FY2024, which is 5108.6% up from last year.
  • According to the latest figures from Q3 2025, Castle Biosciences' Revenue is $83.0 million, which was down 319.3% from $86.2 million recorded in Q2 2025.
  • In the past 5 years, Castle Biosciences' Revenue ranged from a high of $88.0 million in Q1 2025 and a low of $22.8 million during Q2 2021
  • For the 5-year period, Castle Biosciences' Revenue averaged around $54.7 million, with its median value being $50.1 million (2023).
  • Its Revenue has fluctuated over the past 5 years, first surged by 7898.55% in 2021, then crashed by 319.3% in 2025.
  • Castle Biosciences' Revenue (Quarter) stood at $25.0 million in 2021, then surged by 53.11% to $38.3 million in 2022, then skyrocketed by 72.47% to $66.1 million in 2023, then surged by 30.54% to $86.3 million in 2024, then dropped by 3.79% to $83.0 million in 2025.
  • Its Revenue stands at $83.0 million for Q3 2025, versus $86.2 million for Q2 2025 and $88.0 million for Q1 2025.